Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma

Published:2018-10-09 Issue:12 Volume:93 Page:E386-E389
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Tisi Maria Chiara¹^ORCID,Paolini Rossella²,Piazza Francesco³,Ravelli Erika⁴,Tecchio Cristina⁵,Sartori Roberto⁶,Famengo Barbara⁷,D'Amore Emanuele Stefano Giovanni⁷,Carli Giuseppe¹,Perbellini Omar¹,Di Bona Eros¹,Ruggeri Marco¹,Visco Carlo¹

Affiliation:

1. Cell Therapy and Hematology; San Bortolo Hospital; Vicenza Italy

2. Oncohematology; Santa Maria della Misericordia Hospital; Rovigo Italy

3. Hematology and Clinical Immunology Unit, Department of Medicine; University of Padua; Padua Italy

4. Hematology; Valduce Hospital; Como Italy

5. Hematology and Bone Marrow Transplant Unit, Department of Medicine; University of Verona; Verona Italy

6. Hematology Department; San Giacomo Hospital; Castelfranco Veneto Italy

7. Pathology Department; San Bortolo Hospital; Vicenza Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25278/fullpdf

Reference6 articles.

1. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood.,2017

2. S, et al. Outcome in unselected patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) following R-CHOP when stem cell transplantation is not feasible;Kansara;Blood.,2014

3. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study;Arcari;Leuk Lymphoma,2016

4. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma;Ohmachi;J Clin Oncol,2013

5. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines;Castegnaro;Leuk Lymphoma,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells;Journal for ImmunoTherapy of Cancer;2021-07

2. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma;Hematology/Oncology Clinics of North America;2020-10

3. A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib;Annals of Hematology;2020-07-15

4. Bendamustine/cytarabine/rituximab;Reactions Weekly;2018-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3